Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 3c; Provides Q1 & FY19 Operating Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 3c; Provides Q1 & FY19 Operating Guidance

Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR

March 8, 2019 6:57 AM EST

B.Riley/FBR analyst Harshita Polishetty lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $40.00) while maintaining a Buy rating following 4Q report.

On the earnings call, management noted that the company has currently decided to defer the advancement of the entinostat-PD-1... More